Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505
Gilgamesh Pharmaceuticals, a clinical-stage neuroscience biotech developing best-in-class medicines to redefine mental healthcare, announces the successful completion of its Phase 1 Single Ascending Dose (SAD) trial of GM-2505, a novel 5-HT2A receptor agonist. While initially in development for treatment-resistant depression…
CINQCARE Teams with Humana to Provide In-Home Care
CINQCARE, a company committed to deliver health and care where you live, with a deep commitment to Black and Brown communities, and leading health and well-being company Humana Inc. (NYSE: HUM), are teaming up to serve Medicare Advantage members throughout New York. Together, the…
Novel Brain Stimulation Technique Shows Promise in Patients with Hard-to-Treat Depression
By making slight modifications to an already approved brain stimulation technique called transcranial magnetic stimulation (TMS), researchers have reported profound improvement in patients with hard-to-treat depression. Overall, 66% of patients with major depressive disorder who took part in the study responded…
Lunit to Advance Singapore’s Healthcare System with AI-powered Solution for Medical Imaging
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, partners with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore’s public healthcare system. As part of the agreement, Lunit collaborated with CARPL to provide NTT DATA with…
Diabetic Tussin Reintroduces Sugar-Free Cold and Cough Solution for People with Diabetes
Today, Diabetic Tussin®, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves. This restock brings with it the Better Choices for Life mark from the American Diabetes…
Eleos Health and Kipu Health Announce Partnership to Deliver AI-Powered Insights to Behavioral Health Providers
Kipu Health, the leading technology partner for mental health and addiction service providers, and Eleos Health, the leader in AI for behavioral health, today announced a partnership aimed at delivering meaningful insights and efficiencies to behavioral health providers. By enabling Eleos Health’s…
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The results demonstrated a…
PrecisePK Redefines Precision Dosing with Academic Integration, Setting New Standards In Therapeutic Drug Monitoring
Today, PrecisePK announces its significant strides in transforming healthcare in South America through integration into key healthcare and educational institutions. The esteemed Bayesian Model-Informed Precision Dosing (MIPD) software continues its ascendancy, earning recognition from the esteemed Chilean educational institution, Escuela de Química y…
OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced the dosing of the first participant in the Phase 1/2 trial of OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2)…
Densitas® Selects CancerIQ to Power Lifetime Risk, Patient Adherence as Part of its Industry Leading Mammography Quality AI Platform
Densitas Inc., a global leader in artificial intelligence solutions for breast cancer screening, today announced a partnership with CancerIQ, a precision cancer prevention platform, to expand its offering to include CancerIQ’s Tyrer-Cuzick 8 risk calculator, as well as its care management and…
